BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The landscape of innate immune cells is rapidly advancing towa
 rds clinical applications. Multiple published studies in the last year re
 peatedly affirm that targeting myeloid cells rather than the cancer cells
  themselves can shrink tumors\, further providing confidence in their pot
 ential as a clinically effective therapeutic.\n\nThe 4th Annual Tumor Mye
 loid Targeting Therapies Summit captures this progressive momentum and is
  welcoming innate immunity experts frombiopharma and academia to showcase
  novel clinical practices across multiple myeloid subsets.As the field ex
 tends beyond macrophages\, this meeting will also cover MDSCs\, neutrophi
 ls and dendritic cells and delves into their intricate interactions withi
 n the TME for treating resistance in a range of cancers.\n\nHear from the
  likes of MD Anderson\, Gilead Sciences\, Onchilles Pharma\, DEM Biopharm
 a\, NGM Biopharma and many more to uncover translational lessons learned 
 when using combination therapies for tumor eradication\, discover novel t
 argets to assess the efficacy of myeloid cell-based interventions\, decip
 her the complexities of the TME in liquid and solid tumors and more in th
 is year's agenda.\n\nAs we stand at the forefront of ground-breaking disc
 overies\, prioritizing collaboration becomes essential to unveil the most
  effective myeloid-based therapies while addressing key challenges that s
 tand in the way of their development. Join your peers in the innate immun
 ity field to take part in strategic networking and scientific knowledge e
 xchange at this must-attend event.\n\nURLs:Tickets: https://go.evvnt.com/
 2219781-2?pid=185Brochure: https://go.evvnt.com/2219781-3?pid=185\n\nTime
 : 8:00 AM - 5:00 PM\n\nSpeakers: Akshata Udyavar\, Senior Director\, Acty
 m Therapeutics\, Peter Ellmark\, CSO\, Alligator Bioscience\, Stephanie C
 asey Parks\, Principal Scientist\, Amgen\, Mokkram Hossain\, Senior Scien
 tist\, AstraZeneca\, Michael Alonso\, Vice President\, Immunology and Pha
 rmacology\, Bolt Biotherapeutics\, Ananta Paine\, Biomarker Specialist\, 
 Boston University\, Daniel Blumenthal\, Associate Director\, Carisma Ther
 apeutics\, David Reardon\, Clinical Director and Professor of Medicine\, 
 Dana-Farber Cancer Institute\, Kipp Weiskopf\, Co-founder/Fellow\, DEM Bi
 opharma\, Aditya Murthy\, Director\, Immuno-oncology\, Gilead Sciences\, 
 Roshan Kumar\, Senior Director of External Innovations\, HiFiBio Therapeu
 tics\, Miriam Merad\, Director and Professor\, Icahn School of Medicine a
 t Mount Sinai\, Charlene Liao\, President and CEO\, Immune-Onc Therapeuti
 cs\, Osiris M Belaunzaran\, CSO Oncology\, Immunos Therapeutics\, Nagy Ha
 bib\, Professorv Imperial College London\, Pravesh Gupta\, Odyssey Fellow
  MD\, Anderson Cancer Center\, Barbara Platzer\, Associate Director\, Nov
 artis\, Ravindra Gujar\, Senior Scientist\, Onchilles Pharma\, Aram Manga
 sarian\, CEO\, TME Pharma\, Jashodeep Datta\, Assistant Professor\, Unive
 rsity of Miami\, Jean Tchervenkov\, Professor of Surgery\, University of 
 McGill \, Jonathan Cools-Lartigue\, Associate Professor\, University of M
 cGill\n
DTEND:20240613T170000
DTSTAMP:20260512T232259Z
DTSTART:20240611T080000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse
 tts\, 02115\,
SEQUENCE:0
SUMMARY:The landscape of innate immune cells is rapidly advancing towards 
 clinical applications. Multiple published studies in the last year repeat
 edly aff...
UID:bd2d8c7a-f59c-432f-833a-1d539947c65a
END:VEVENT
END:VCALENDAR